Roche Bullish Despite Biosimilars Battering
Pharma Sales Down By 7% in Q4
Its older oncology products are sinking but the Swiss major is confident about coming through COVID-19 in a strong position.
You may also be interested in...
Roche’s sales in 2020 increased by 1%, at constant exchange rates, to CHF 58.3bn, led by 14% growth in its diagnostics division.
After failing in five earlier trials, Actemra shows significant life-saving benefits for patients with severe COVID-19.
Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."